Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230032/S005

AvertD and AvertD Buccal Sample Collection Kit

AutoGenomics, Inc. · Decision date May 20, 2026

FDA DECISIONP230032/S005

What did the FDA approve?

FDA records P230032/S005 as a supplement to PMA P230032, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated May 20, 2026.

FDA approval order statement

Approval of the revised protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P230032.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Clinical Toxicology
Decision date
May 20, 2026
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P230032/S005
Regulatory pathway
PMA supplement
Product code
QZH
Decision code
APPR
Decision date
May 20, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Opioid use disorder genetic risk variant detection system and collection kit.

Product code
QZH
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P230032/S003 · Related supplement

    AvertD and AvertD Buccal Sample Collection Kit

  2. P230032/S004 · Related supplement

    AvertD and AvertD Buccal Sample Collection Kit

  3. P230032/S005 received

    Application receipt date recorded by FDA.

  4. P230032/S005 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P230032. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230032

Product / regulatory recordCompanyPathwayDecision dateSource
AutoGenomics, Inc.PMA supplementJan 29, 2026FDA
AutoGenomics, Inc.PMA supplementApr 10, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

AutoGenomics, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1600 Faraday Ave., Carlsbad, CA, 92008

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records